Abiraterone and increased survival in metastatic prostate cancer
about
Emerging molecularly targeted therapies in castration refractory prostate cancerStructures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001Abiraterone in metastatic prostate cancer without previous chemotherapyImmunobiology and immunotherapy in genitourinary malignanciesMolecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancerGaleterone for the treatment of advanced prostate cancer: the evidence to dateCYP17 inhibitors in prostate cancer: latest evidence and clinical potentialA Perspective of Immunotherapy for Prostate CancerMouse Models in Prostate Cancer Translational Research: From Xenograft to PDXPerspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigmSaudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancerTherapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate CancerAndrogen Receptor Structure, Function and Biology: From Bench to BedsideResistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate CancerMechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate CancerTasquinimod in the treatment of castrate-resistant prostate cancer - current status and future prospectsPatient experience in the treatment of metastatic castration-resistant prostate cancer: state of the sciencePrognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer: A Systematic Review and Meta-analysisHormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancerSequence of treatment in locally advanced and metastatic renal cell carcinomaMechanisms of resistance in castration-resistant prostate cancer (CRPC)Persistent androgen receptor addiction in castration-resistant prostate cancerEmerging mechanisms of resistance to androgen receptor inhibitors in prostate cancerSingle-cell analyses of circulating tumor cellsPrevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression ModelAbiraterone in the management of castration-resistant prostate cancer prior to chemotherapyTargeting molecular resistance in castration-resistant prostate cancerODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancerDrug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategiesImmune Infiltration and Prostate CancerProgress of molecular targeted therapies for prostate cancersMetastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapyRenin-angiotensin system blockade: Its contribution and controversyAbiraterone in prostate cancer: a new angle to an old problemMedical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistantCombining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapyImmunotherapy for prostate cancer: recent developments and future challengesSystemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.Circulating tumors cells as biomarkers: progress toward biomarker qualificationDynamic changes in numbers and properties of circulating tumor cells and their potential applications
P2860
Q21284745-3DA7EDE3-5A71-459B-8FCB-7CDD350662C5Q24302773-7578A984-B5F5-42BC-9E4C-18138D77C9FCQ24612084-02725DEF-4B70-43B8-8A10-C7086FE899AAQ26738668-BDA60737-F593-48E2-8C2B-E434DA88EC0DQ26739708-CB0D6AE0-F381-4A55-A87D-EEAD68F3028CQ26739887-4F4FCCE7-1611-4FC2-8A80-E38078B91CDFQ26740070-C78CF34B-491E-4631-8FDE-7AC3B6D440A8Q26741277-8ACE828C-4F30-4CF6-BDF0-92FF7D0001FEQ26746524-99C99A52-A973-463D-9E43-B25E04AD0F12Q26747699-CAB012D7-6A9A-47AA-AA92-FDB5AFC16DC6Q26747782-6B08ACDD-54AF-4B10-8467-61F3E44C2EA7Q26750620-D4CF0F44-F8C2-4140-9B72-C8C84CFB1BEBQ26750866-F2EDFCAD-2335-4D4E-AB2B-19BE30F6857CQ26751237-1B721AFA-679E-4B47-BA43-7E3DE8249D46Q26766638-17C9A5ED-3D0C-477C-8DED-36BED4D2F171Q26770428-8AFE2535-548F-492B-BF5E-893E9FD08CFCQ26772883-170081B8-8570-4326-B252-CB6122D96FB1Q26773406-F684E91B-537A-484D-BCFB-1B5804F54677Q26773634-5019A282-E6D9-4819-82B4-E1F9A063267EQ26773653-1C5DB2BF-5398-4F9C-ACF2-ECD60E676AFFQ26774221-8A0CC93C-6DEB-41E9-966C-2E5024F1B57BQ26777163-F90B47BB-67C7-4042-A569-B4B813BD0A2CQ26777310-01320DB7-4922-40A2-A314-6253DFCB3AF6Q26778816-749563AA-154C-44AA-A2C6-6A6C04E85A77Q26783861-915FF6B8-C4D7-48AE-9B3D-9F0DCAB08338Q26786543-087EABCF-4914-4DC0-8884-0138088F31D5Q26795445-047CB994-A4CB-4E3F-862C-5E96CEE98B25Q26796568-1209B3DC-AB9F-49A0-B77D-C64B3633D290Q26796704-10B27FF9-DF17-46F0-A490-516275DC4411Q26798412-F4B0E3F8-8C60-4E7A-814F-E0F538954E53Q26823014-1CE138E4-AD02-4351-AF4F-7DBD86370F9BQ26825053-5D2F506F-9DB4-4369-B255-BACED66BD892Q26827221-6CB4B336-2F14-460A-A29A-51D08EB8B546Q26828810-2AB0F1AB-2B05-4EF3-9D81-D4F51F85584CQ26851177-A50A8418-1618-4F69-A213-CC5538482E5FQ26851608-7B7093F2-7BF9-46D3-8360-94810929756FQ26852388-3B08B3DD-2684-4B9E-BA7B-F2F2165BC60BQ26852544-65941856-9C9A-489E-AE5B-79533D8A089BQ26852579-CFD44152-B37A-4829-A5D4-7459BB631BB0Q26853569-A0640F42-EB4A-4244-AECA-8641D517677F
P2860
Abiraterone and increased survival in metastatic prostate cancer
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Abiraterone and increased survival in metastatic prostate cancer
@ast
Abiraterone and increased survival in metastatic prostate cancer
@en
type
label
Abiraterone and increased survival in metastatic prostate cancer
@ast
Abiraterone and increased survival in metastatic prostate cancer
@en
prefLabel
Abiraterone and increased survival in metastatic prostate cancer
@ast
Abiraterone and increased survival in metastatic prostate cancer
@en
P2093
P2860
P3181
P356
P1476
Abiraterone and increased survival in metastatic prostate cancer
@en
P2093
Andrea Zivi
Arturo Molina
Aude Fléchon
COU-AA-301 Investigators
Charles J Ryan
Christopher J Logothetis
Christopher M Haqq
Cora N Sternberg
Diletta Bianchini
Eleni Efstathiou
P2860
P304
P3181
P356
10.1056/NEJMOA1014618
P407
P50
P5008
P577
2011-05-01T00:00:00Z